ONL Therapeutics

Biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors.

Launch date

2011

Employees

Market cap

Enterprise valuation

Ann Arbor Michigan (HQ)

Date	Investors	Amount	Round
-	Small Business Innovation Research (SBIR)	N/A	-
Jul 2014	Capital Community Angel Investors	$500k	Seed
Nov 2014	N/A	$1.4m	Grant
Aug 2016	N/A	$916k	Debt
Mar 2017	National Institutes of Health National Eye Institute	$1.0m	Grant
May 2017	InvestMichigan Novartis Capital Community Angel Investors Western Michigan University	$4.3m	Series A
Aug 2019	Capital Community Angel Investors Invest Michigan	$3.0m	Convertible
Dec 2020	ONL Therapeutics Johnson & Johnson Innovation Kaitai Capital Bios Partners Capital Community Angel Investors Biosciences Research and Commercialization Center (BRCC) InFocus Capital Partners PSQ Capital Michigan Capital Network	$46.9m	Series B
Mar 2023*	Johnson & Johnson Innovation Kaitai Capital Visionary Ventures Bios Partners Capital Community Angel Investors Western Michigan University Biosciences Research and Commercialization Center (BRCC) PSQ Capital Michigan Capital Network ExSight Ventures Alpine Visionary Venture Mayewell Capital	$15.0m Valuation: $235m	Series C
Sep 2024*	Johnson & Johnson Innovation Visionary Ventures Novartis Venture Fund Bios Partners	$65.0m	Series D
Total Funding		AUD212m

Tech stackLearn more about the technologies and tools that this company uses.

Recent News about ONL Therapeutics